Odyssey Therapeutics seeks $238.3 million in US IPO
Updated
Updated · Bloomberg · May 4
Odyssey Therapeutics seeks $238.3 million in US IPO
8 articles · Updated · Bloomberg · May 4
The Boston-based clinical-stage biotech plans to sell 13.2 million shares at $16 to $18 each, according to a Monday filing with the US Securities and Exchange Commission.
At the top of the range, Odyssey would be valued at about $809.9 million based on the outstanding shares listed in the filing.
The company focuses on developing treatments for autoimmune and inflammatory diseases, positioning the offering as a funding source for its clinical-stage pipeline.
Can Odyssey's promising drugs outpace its massive cash burn in a selective IPO market?
Will Odyssey’s oral pills disrupt the billion-dollar market for injectable autoimmune treatments?